Ep. 214 Ken Shreve: Improving Portfolio Health With Medical Stocks
Investing With IBD
00:00
How to Avoid Speculative Names in Biotechs
Rousha: Is there anything that you do to kind of just make sure you're dealing with higher quality and the less, you know, a little bit lower risk? Rousha: One of the first areas that I start to go through on the weekends is the marksman growth to 50. That's just casting a wide enough net. And what I'll look there, you'll just start seeing the higher quality names within a biotech or medical products starting to come into those screens.
Transcript
Play full episode
